Table 6.
Incidence of endometrial cancer. Events after 2 versus 5 years of tamoxifen treatment.a
| Years after surgery | TAM 2 yrs (n = 2085) |
TAM 5 yrs (n = 1992) |
HR 5 vs 2 yrs |
95% CI | SHR 5 vs 2 yrs |
95% CI |
|---|---|---|---|---|---|---|
| Number of events | ||||||
| ≥2 | 42 | 70 | 1.65 | 1.12–2.42 | 1.81 | 1.23–2.66 |
| 2–5 | 6 | 20 | 3.49 | 1.40–8.71 | 3.54 | 1.42–8.82 |
| 5–15 | 18 | 32 | 1.69 | 0.95–3.01 | 1.93 | 1.07–3.47 |
| 15 – | 18 | 18 | 1.00 | 0.52–1.93 | 0.96 | 0.49–1.85 |
CI = confidence interval; HR = hazard ratio; SHR = subhazard ratio; TAM = tamoxifen.
a
22 patients were diagnosed with contralateral breast cancer before the randomization. Furthermore, 7 patients in the treatment group of 2 years TAM and 18 patients in that of 5 years TAM were diagnosed with endometrial cancer before (the) randomization. These patients were excluded in this analysis.